NKTR Nektar Therapeutics
$34.42
Nektar Therapeutics (NKTR) Earnings News
Earnings press releases, previews and reviews for Nektar Therapeutics (NKTR), newest first. Our most recent is review: Nektar's Per-Share Beat Owes Much to Dilution as Its Rezpeg Phase 3 Program Moves Into Execution, With Shares Down 48% Since the Last Report.
Thursday
November 12, 2026
7:45 PM ET
Nektar's Per-Share Beat Owes Much to Dilution as Its Rezpeg Phase 3 Program Moves Into Execution, With Shares Down 48% Since the Last Report
Earnings Whispers · Review
Thursday
November 12, 2026
4:15 PM ET
Nektar Therapeutics Announces Third Quarter 2026 Financial Results
Wednesday
November 4, 2026
6:10 PM ET
Nektar Reports With Shares Halved, Phase 3 Spending Rising and a Jury Trial to Explain
Earnings Whispers · Preview
Tuesday
October 27, 2026
6:00 PM ET
Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets
Thursday
August 13, 2026
4:15 PM ET
Nektar Therapeutics Announces Second Quarter 2026 Financial Results
Tuesday
July 28, 2026
6:00 PM ET
Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets